Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • History
    • Our Leadership
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Multiple Myeloma
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • What is Gene Therapy?
    • Gene Therapy Techniques
    • Clinical Trials
    • Our Pipeline
  • Our Products
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Corporate Presentation
  • Our Value Model
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Jenn Snyder

    VP, Corporate Communications

    (617) 448-0281

    JSnyder@bluebirdbio.com

  • Catherine Falcetti

    Senior Director, Corporate Communications

    (339) 499-9436

    CFalcetti@bluebirdbio.com

Investor Contacts

  • Ingrid Goldberg

    VP, Investor Relations

    (857) 217-0490

    IGoldberg@bluebirdbio.com

  • Elizabeth Pingpank

    Director, Investor Relations

    (617) 914-8736

    EPingpank@bluebirdbio.com

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

  • Read more about bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

  • Read more about bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

  • Read more about bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

  • Read more about bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

  • Read more about bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™

  • Read more about European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO™

bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

  • Read more about bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

Benjamin Burnett, Ph.D.

    Benjamin Burnett, Ph.D.
    Stifel

    bluebird bio Appoints William R. Sellers, M.D. to Board of Directors

    • Read more about bluebird bio Appoints William R. Sellers, M.D. to Board of Directors

    bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    • Read more about bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

    Pagination

    • First page « First
    • Previous page ‹ Previous
    • …
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Current page 7
    • Page 8
    • Page 9
    • Page 10
    • Page 11
    • …
    • Next page Next ›
    • Last page Last »
    Subscribe to

    Quick Links

    • Patients & Advocacy
    • Investors & Media
    • Careers
    • Contact Us

    CONTACT INFO

    info@bluebirdbio.com

    clinicaltrials@bluebirdbio.com

    investor@bluebirdbio.com

    medinfo@bluebirdbio.com

    Live - Terms & Privacy

    • Terms of Service
    • Privacy Policy
    • Cookie Notice
    • Sitemap
    © 2021 bluebird bio, Inc. All Rights Reserved. Corp-GBL-00011 05/19

    Live - Social Links